Printer Friendly

Aridis Pharmaceuticals Begins Patient Enrollment in International Study of Aerucin for Treatment of Acute Pneumonia.

M2 PHARMA-August 3, 2017-Aridis Pharmaceuticals Begins Patient Enrollment in International Study of Aerucin for Treatment of Acute Pneumonia

(C)2017 M2 COMMUNICATIONS

- San Jose, California-based anti-infectives and immunotherapies specialist Aridis Pharmaceuticals, Inc. is actively enrolling patients in a global pivotal study of Aerucin, the company's broadly reactive monoclonal antibody being developed to treat acute pneumonia caused by Gram-negative bacteria Pseudomonas aeruginosa (P. aeruginosa), the company said.

The randomised, double-blinded, placebo-controlled trial is ongoing in 14 countries worldwide.

Aerucin is a fully human monoclonal IgG1 antibody that binds to alginate, a cell surface polysaccharide that is widely distributed on P. aeruginosa. Once bound, Aerucin improves recognition and destruction by the immune system through enhanced complement deposition.

Aerucin has proven effective in promoting phagocytic killing of a wide range of both mucoid and non-mucoid P. aeruginosa clinical isolates, including antibiotic-resistant strains from pneumonia and cystic fibrosis patients.

In an animal model of acute pneumonia, Aerucin protected mice from lethal P. aeruginosa challenges at doses as low as 0.004 mg/kg. It also protected animals against eye infections in a keratitis model and sepsis in a systemic infection model.

These studies support both therapeutic and prophylactic uses of Aerucin against a broad range of P. aeruginosa infections.

Aridis is a privately held biopharmaceutical company applying proprietary monoclonal antibody discovery technology to produce novel infectious disease focused therapies.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 3, 2017
Words:236
Previous Article:X4 Pharmaceuticals to Collaborate with Yale University to Study WHIM Syndrome.
Next Article:Bolder BioTechnology Begins Clinical Trial of BBT-015 for Treating Neutropenia and Acute Radiation Syndrome.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters